Detailseite
Projekt Druckansicht

Knockout mice and myocyte cell models to study the pathogenesesis and phenotype rescue of muscular plectinopathies

Fachliche Zuordnung Molekulare und zelluläre Neurologie und Neuropathologie
Förderung Förderung von 2009 bis 2016
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 101925924
 
Erstellungsjahr 2017

Zusammenfassung der Projektergebnisse

The most common disease caused by plectin deficiency, epidermolysis bullosa (EB)-MD, is characterized by muscular dystrophy and severe skin blistering. EB-MD patients and plectin-deficient mice display massive desmin aggregation, the hallmark of myofibrillary myopathies (MFMs). Our previous studies had shown that the 4 major plectin isoforms expressed in muscle are crucial for the integrity of myofibers by specifically targeting and anchoring desmin IF networks to Z-disks, costameres, mitochondria, and the nuclear/SR membrane system. Having established myocyte cell culture systems mimicking the pathological hallmarks of MFMs in phase I of our FOR1228 project and taking advantage of our ample collection of conditional and muscle isoform-specific plectin knockout mouse lines, our major objectives for project phase II were: (i) To gain a better understanding of the pathogenesis underlying plectinopathies (and MFMs in general) by unraveling the mechanisms of plectin isoformmediated IF-docking at distinct cellular locations, including the neuromuscular synapse, ii) to develop and assess treatment concepts for the removal of protein aggregates from MFM myofibers, including phenotype rescue attempts through gene transfer; and iii) to analyze the biomechanical properties and mechanotranduction potential of plectin-deficient myocytes and myofibers in comparison to wild-type and other cell types. Our studies to objective (i) revealed that plectin isoform 1 (P1) by binding and thereby recruiting desmin IFs to myonuclei affects the nuclear morphology and gene expression pattern, and thus plays an important role in mechanotransduction. Equally important roles were revealed for P1d and P1b in affecting structural and functional features of sarcomeric Z-disks and mitochondria, respectively, while P1f could be shown to be of vital importance for neurosynapse integrity and to affect muscle cell metabolism, i.e. glucose uptake. The outcome of objective (ii)-based studies was equally satisfying, as 4-PBA, a chemical chaperon, was found to lead to the removal of protein aggregates, ex vivo in MFM myotube cultures as well as in vivo in mouse muscles, combined with improved muscle performance. This study provided the basis for ongoing initiatives for clinical test trials with MFM patients. Under this objective we also prepared and tested cDNA expression plasmids for plectin “mini” versions, setting up the stage for gene therapeutic approaches with MFM mice and eventually human patients. In the framework of objective (iii), we could show that dysfunctional plectin severely affects the stiffness, adhesion strength, and cytoskeletal dynamics of myoblasts with partially divergent implications for other cell types. In a series of complementary studies, the dominant role of plectin in mechanotransduction, as revealed in our studies with muscle cells, could be confirmed and extended to other cell systems, including vascular endothelial cells, fibroblasts, keratinocytes, and different cancer cell systems. In all, our results significantly advanced our understanding of the molecular mechanisms underlying plectinopathies and other MFMs, and opened a way for a possible treatment of related diseases.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung